
    
      In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of
      three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the
      final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
    
  